Navigation Links
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Date:6/12/2008

clinical trials at high and low doses of PTC124, TEPD assessments showed statistically significant improvements of mean CFTR-dependent chloride secretion in the airways.

The Phase 2a extension study in Israel assessed 3 months of oral PTC124 therapy at two different dose levels in 19 adult men and women with nonsense- mutation-mediated CF who had participated in a prior short-term PTC124 Phase 2a study. More than 90% of the patients had chronic CF-related lung infection and also had CF-induced pancreatic insufficiency. Results from the study showed that treatment with PTC124 resulted in statistically significant (p< 0.001) improvements in CFTR function as measured by TEPD in both dose groups. The proportion of patients showing improvement in TEPD chloride secretion increased over time in the extension study. Trends towards improvements in mean FEV1 and FVC values were observed. Baseline data showed that CF patients cough a remarkable 643 times per day on average, with a range of 324 to 1,569 coughs per day. In comparison, healthy individuals generally cough fewer than 16 times per day, according to the European Respiratory Journal (Hsu 1994). Patients receiving PTC124 experienced a mean [28%] decrease in cough frequency by the end of three months of therapy (p< 0.01). PTC124 was generally well tolerated, resulting in excellent mean compliance with the treatment regimen ( >90%).

"Three months of treatment with PTC124 in nonsense-mutation-mediated CF patients was associated with time-dependent improvements in nasal TEPD chloride conductance, pulmonary function and cough -- important markers suggesting the potential for benefit in patients with CF," stated Dr. Wilschanski. "PTC124 increases CFTR-mediated chloride secretion in patients with a variety of nonsense mutation types, which suggests a broad spectrum of activity across one of the major subpopulations in CF."

Dr. Kerem added, "The impact on cough that we observed in this study by objective
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... nationally available 2015 Express Scripts Medicare ® Prescription ... network featuring Walgreens (NYSE: WAG ) (NASDAQ: ... value, choice and clinical support  for their Medicare dollars. ... Scripts Medicare Value or Choice ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:9/30/2014)... the health and safety of Canadians is our government,s highest priority.  ... tools at its disposal to help ensure that the drugs Canadians ... that end, Health Canada has taken ... of all drug products from three plants in ... Apotex Pharmachem India Pvt Ltd , Apotex Research Private Limited ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... 2011 Reportlinker.com announces that a new market ... Hospital Mammography Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
... 20, 2011 Perrigo Company (Nasdaq: PRGO; TASE) today ... acquire substantially all of the assets of Paddock Laboratories, ... generic pharmaceutical products for approximately $540 million in cash. ... a result of the acquisition of Paddock,s assets. The ...
Cached Medicine Technology:Reportlinker Adds Hospital Mammography Census 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 3Perrigo to Acquire Assets of Paddock Labs for $540 Million 4Perrigo to Acquire Assets of Paddock Labs for $540 Million 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... Beverly Hills, California (PRWEB) October 01, 2014 ... relationship expert, Dr. Kathleen Mojas is celebrating 20 years ... she has assisted hundreds of people to achieve greater ... released an important list of warning signs and suggestions ... relationship. , Dr. Mojas explains: “Believe it or ...
(Date:10/1/2014)... Innovations announces the upcoming airing of ... Monday, October 20, 2014 at 7:30 a.m. EST/PT via ... behind the scenes to learn about Break the Cycle’s ... the practical help and information Break the Cycle provides ... signs of abuse, how to navigate the legal system, ...
(Date:10/1/2014)... October 01, 2014 NoteSwift Inc., announced ... versions 10.0, 12.1 and 13.0. NoteSwift is the bridge ... commands to navigate and document clinical information at the ... spends creating a patient note by more than half ... the major pain points providers state impedes EHR use ...
(Date:10/1/2014)... 01, 2014 Scientists at the University ... that target immune system proteins has the power to ... posted details of the new study on their website. ... , Researchers in the UWA School of Pathology and ... to mice with mesothelioma with promising results. , ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... software medication solution reduces complexity in, patient-specific medication ... ... LAS VEGAS, ASHP, Dec. 3 Ushering in ... OMCL ) a leading provider,of system solutions ...
... with Centers of Influence, POWAY, Calif., Dec. ... leading provider of medical diagnostic imaging systems,and services ... the signing of a letter of agreement with ... of the agreement, the fifth since the inception ...
... advertisements are appearing on television, the bulk of ... spend annually to market their products is targeted ... students. , A literature review by researchers ... the Regenstrief Institute, Inc. published in the December ...
... , , MONDAY, Dec. 3 (HealthDay News) -- Avandia, a ... bone loss, according to a new study conducted in mice. ... may speed osteoporosis, the thinning of the bones that can ... appear in the Dec. 2 online issue of Nature ...
... ANGELES, Dec. 2 Hurricane Katrina was one ... and was the costliest (at an,estimated $86 billion.) ... in the aftermath. Witnessing the,destruction/displacement from the West ... to take his new school training techniques, with,old ...
... Everything from Christmas trees to fake snow can trigger symptoms, ... It,s easy for the holidays to become the season ... or other allergies and asthma, say experts at the American ... preventive measures can cut symptoms to a minimum, they say. ...
Cached Medicine News:Health News:Omnicell Debuts Industry's First Total Automated Patient-Specific Management Solution 2Health News:Omnicell Debuts Industry's First Total Automated Patient-Specific Management Solution 3Health News:Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement 2Health News:Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement 3Health News:Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement 4Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:Diabetes Drug Avandia Could Weaken Bones 2Health News:CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors 2Health News:CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors 3Health News:'Tis the Season For Allergy, Asthma 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Adjustable speed vortex with inter-changeable heads , 110 V...
Inquire...
Adjustable speed vortex with inter-changeable heads, 110 V...
Medicine Products: